Composition, form of production and packaging
Tablets of white color, flat-cylindrical, with a facet.
1 tab.
ipidakrine hydrochloride (in the form of monohydrate) 20 mg
Excipients: Ludipress (lactose monohydrate 93%, povidone 3.5%, crospovidone 3.5%) - 65 mg, sodium carboxymethyl starch - 14 mg, calcium stearate - 1 mg.
10 pieces. - packings cellular planimetric (5) - packs cardboard.
50 pcs. - polymer cans (1) - packs of cardboard.
50 pcs. - banks of dark glass (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the print edition of 2007.
PHARMACHOLOGIC EFFECT
Cholinesterase inhibitor. Stimulates neuromuscular transmission and conduction of excitation along the nerves and cells of smooth muscles due to blockade of the potassium channels of the excitable membrane and inhibition of cholinesterase activity, enhances the effect of acetylcholine, serotonin, histamine, oxytocin on smooth muscle (but does not affect the potassium chloride action).
PHARMACOKINETICS
Suction
After taking the drug inside, ipidacrin is rapidly absorbed from the digestive tract, mainly from the duodenum, to a lesser extent - from the thin and iliac; about 3% of the dose is absorbed from the stomach. C max in blood plasma is reached after 25-30 minutes after taking the drug in low doses and 1 hour after taking in the dose at the rate of 10 mg / kg of body weight.
Distribution
Epidacrine rapidly penetrates from the blood into the tissues, so after reaching the equilibrium state, about 2% of the accepted dose of the drug remains in the blood serum. The binding with plasma proteins is 40-55%.
Metabolism and excretion
Half-life is 0.7 hours.
Ipidacrin is biotransformed in the liver and is excreted partially with bile, and mostly by the kidneys, mainly due to tubular secretion, about 1/3 - by glomerular filtration, with only 3.7% of the dose being excreted unchanged.
INDICATIONS
- diseases of the peripheral nervous system (neuritis, polyneuritis, polyneuropathy, polyradiculopathy);
- bulbar paralysis and paresis;
- The recovery period for organic lesions of the CNS, accompanied by motor disorders;
- Myasthenia gravis and myasthenic syndromes;
- in the complex therapy of demyelinating diseases;
- Alzheimer's disease and senile dementia of the Alzheimer's type;
- weakness of labor activity;
atony of the intestine.
DOSING MODE
The drug is administered to adults .
With lesions of the peripheral nervous system , 20 mg 3 times / day are prescribed.
With myasthenia gravis, myasthenic syndromes and dimielinizing nervous system lesions, the recommended single dose is 20-40 mg; frequency of reception 4-5 times / day. The maximum daily dose is 180-200 mg.
For treatment and prevention of intestinal atony appoint 15-20 mg 2-3 times / day for 1-2 weeks.
For the treatment of Alzheimer's disease and mnestic disorders of different genesis , an individual choice of the dosing regimen is required. The average dose is 10-20 mg 2-3 times / day. The duration of therapy is from 1 month to 1 year.
To stimulate labor, the drug is prescribed in a dose of 20 mg once. If the effect is insufficient, the preparation is repeated 1-2 times with an interval between doses of 1 hour.
SIDE EFFECT
On the part of the digestive system: anorexia, hypersalivation, nausea, vomiting, increased peristalsis, diarrhea, jaundice.
From the side of the central nervous system: dizziness (after repeated admission), ataxia.
Allergic reactions: skin itch, rash.
Other: bronchospasm, bradycardia (manifestation of m-cholinomimetic action).
CONTRAINDICATIONS
- epilepsy;
- extrapyramidal disorders with hyperkinesia;
- angina pectoris;
- pronounced bradycardia;
- bronchial asthma;
- propensity to vestibular disorders;
- Pregnancy;
- the period of lactation (breastfeeding);
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The drug is contraindicated for use in pregnancy and lactation.
SPECIAL INSTRUCTIONS
With caution appoint with gastric ulcer, thyrotoxicosis, diseases of the cardiovascular system. It is also necessary to take into account the possible increase in the tone of the uterus.
The drug is well tolerated, side effects occur rarely (in 6.5% of cases), mildly expressed and, as a rule, do not require drug withdrawal (rapid elimination prevents cumulation and the occurrence of side effects).
During the period of drug use, you should not drink alcohol.
Impact on the ability to drive vehicles and manage mechanisms
During the period of treatment, patients should avoid driving motor vehicles and other activities that require a high concentration of attention and speed of psychomotor reactions.
OVERDOSE
Treatment: withdrawal of the drug, the use of m-holinoblokatorov (atropine sulfate, cyclodol).
DRUG INTERACTION
When combined, increases the sedative effect of drugs with a depressing effect on the central nervous system, the effect of other inhibitors of cholinesterase and m-cholinomimetics.
Against the background of the use of other cholinergic drugs, the risk of a cholinergic crisis in patients with myasthenia gravis increases.
When combined, beta-blockers increase the risk of developing bradycardia.
When combined, weakens the effect of local anesthetics, antibiotics, potassium chloride.
Atropine and metocinia iodide reduce the severity of side effects of high doses of ipidacrine.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List A. The drug should be stored in a dry, protected from light and out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 2 years.
